184 related articles for article (PubMed ID: 11700768)
1. Embarrassed firms slash prices for AIDs drugs.
Boseley S
N Z Med J; 2001 Oct; 114(1141):440. PubMed ID: 11700768
[No Abstract] [Full Text] [Related]
2. Glaxo drops drug prices, AIDS foundation drops suit.
AIDS Policy Law; 2003 May; 18(10):6. PubMed ID: 12809097
[No Abstract] [Full Text] [Related]
3. [GlaxoSmithKline again lowers prices of drugs for HIV/AIDS and malaria].
Krankenpfl J; 2002; 40(7-9):222-3. PubMed ID: 12514863
[No Abstract] [Full Text] [Related]
4. Companies reduce prices for HIV drugs in developing countries.
Gottlieb S
Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
[TBL] [Abstract][Full Text] [Related]
5. Drug makers to cut prices for developing countries.
AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655
[TBL] [Abstract][Full Text] [Related]
6. Uganda cuts AIDS drug deal.
IAPAC Mon; 2001 Feb; 7(2):40. PubMed ID: 11302022
[No Abstract] [Full Text] [Related]
7. World Trade Organization still threatens supply of affordable AIDS drugs.
Hagmann M
Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
[No Abstract] [Full Text] [Related]
8. Bush declines to support drug companies' line on AIDS profits.
Dickson D
Nature; 2001 Mar; 410(6824):3. PubMed ID: 11241998
[No Abstract] [Full Text] [Related]
9. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
James JS
AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
[TBL] [Abstract][Full Text] [Related]
10. AIDS research. Drug trials without the drugs?
Cohen J
Science; 2003 May; 300(5623):1212-3. PubMed ID: 12764159
[No Abstract] [Full Text] [Related]
11. Thank God for rich women with mustaches.
Friedman JH
Med Health R I; 2001 Jul; 84(7):222-3. PubMed ID: 11482273
[No Abstract] [Full Text] [Related]
12. Cut-rate AIDS.
Golden F
Time; 2001 Mar; 157(11):68. PubMed ID: 11276822
[No Abstract] [Full Text] [Related]
13. Cheaper AIDS drugs due for Third World.
Brown P
Nature; 2000 May; 405(6784):263. PubMed ID: 10830927
[No Abstract] [Full Text] [Related]
14. An unequal activism for an unequal epidemic?
Selemogo M
Dev World Bioeth; 2005 May; 5(2):153-68. PubMed ID: 15842724
[TBL] [Abstract][Full Text] [Related]
15. Indian company seeks US approval for generic AIDS drugs.
Nature; 2004 Aug; 430(7001):716. PubMed ID: 15306779
[No Abstract] [Full Text] [Related]
16. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
17. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
18. Drug firms drop drug case against South Africa.
AIDS Policy Law; 2001 May; 16(9):3. PubMed ID: 11668825
[No Abstract] [Full Text] [Related]
19. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
20. AIDS drugs. Brazil, Thailand override big pharma patents.
Cohen J
Science; 2007 May; 316(5826):816. PubMed ID: 17495145
[No Abstract] [Full Text] [Related]
[Next] [New Search]
